Mission Bio Taps Dr. Zivjena Vucetic as Chief Medical Officer

Mission Bio, a precision medicine company, has appointed Zivjena Vucetic, M.D., Ph.D., as Chief Medical Officer. A physician-scientist with more than 15 years of experience in diagnostics and emerging platforms, Vucetic has directed medical and scientific strategies that move technologies from discovery to clinical settings, building regulatory confidence and supporting adoption across multiple therapeutic areas.

“Zivjena brings a proven record of translating breakthrough science into clinical adoption at global scale,” said Brian Kim, CEO of Mission Bio. “Her leadership strengthens our ability to deliver evidence and confidence to our partners as they bring precision therapies to patients. With her expertise, Mission Bio is positioned to set the standard for how single-cell multi-omics informs the next generation of drug development and clinical research.”

Experience

Vucetic most recently served as Chief Medical Officer and Senior Vice President at Beckman Coulter Diagnostics, where she directed medical strategy across a multibillion-dollar global portfolio and advanced blood-based biomarker programs in Alzheimer’s and other neurodegenerative diseases. At Karius, she built the clinical and regulatory foundation for an infectious disease sequencing test that achieved FDA Breakthrough Device designation. She has also held leadership roles at Clinical Genomics, Ortho Clinical Diagnostics and Fujirebio Diagnostics, guiding end-to-end validation, payer engagement, and publication strategy while building strong partnerships with pharma and academic consortia.

“Throughout my career, I have focused on building the clinical evidence and regulatory confidence required to move new diagnostics from concept to adoption,” said Vucetic. “Mission Bio’s single-cell multi-omics platform carries the same potential to shift standards in precision medicine, and I am eager to help extend its impact across cancer, cell and gene therapy, and therapeutic development.”